Coronavirus Variants Rapid Response Network | Réseau de réponse rapide aux variants du coronavirus

CMCM MBMC Montreal Behavioural Medicine Centre

COVID-END COVID-19 Evidence Network to support Decision-making ... in Canada

COVID-19 Living Evidence Synthesis #10
(Version 10.3: 2nd March 2022)

Questions

1. How does the level of vaccine efficacy / effectiveness (VE) against COVID-19 infection, hopsitalisation, and death change over time (>112 days) in individuals who have received a complete primary COVID-19 vaccine series?
2. How does the level of VE against COVID-19 infection, hopsitalisation, and death change over time (>84 days) in individuals who have received a complete primary COVID-19 vaccine series plus an additional dose?

Findings

1. A visual summary of the primary series VE against any infections, hospitalisations, and deaths are presented in Tables 1, 4, and 7, respectively. For delta-outcomes the summaries are presented in Tables 2, 5, and 8; and for omicron-related outcomes in Tables 3, 6, and 9.
2. A visual summary of the primary series + additional dose VE against any infections and hospitalisations are presented in Tables 10, 11, and 12, respectively. These tables include variant specific information where available.

Methods are presented in Box 1 and in the related appendices.

Overall (from the initiation of this review), 13,003 studies were title and abstract screened, 663 were full-text appraised, and 27 used to complete this summary. The reasons for excluding the 636 studies are reported in **Appendix 5**.

Fifteen new studies (marked in blue in **Appendix 1**) have been added since the previous version of this evidence synthesis (November 2021).

Box 1: Our approach

We retrieved candidate studies and updates to living evidence syntheses on vaccine effectiveness using the following mechanisms: 1) search on the National Institute of Health (NIH) iSearch COVID-19 portfolio and EMBASE; 2) systematic scanning of COVID-END Forum website, McMaster Health Forum website, and citations of systematic reviews on this topic; and 4) cross-check with updates from the VESPa team. We included studies and updates to living evidence syntheses identified up to five days before the version release date. We did not include press releases unless a preprint was available. A full list of included and excluded studies is provided in **Appendix 1 and 5**, respectively. A glossary is provided in **Appendix 3**.

Prioritized outcome measures: Infection, hospitalisation, and death.

Data extraction: We prioritised any infection data over symptomatic or asymptomatic and total population data over sub-groups. We extracted data from each study using a standard template with peer-review to confirm information **Appendix 6**. Only data from four of the Health Canada vaccines (BNT162b2, mRNA-1273, ChAdOx1, and Ad26.COV2.S) and only delta and omicron VOC data were extracted for sub-analyses. VOC data was determined directly when reported by study authors.

Critical appraisal: We assessed risk of bias and certainty of evidence. **Risk of bias:** assessed in duplicate for individual studies using an adapted version of ROBINS-I (see **Appendix 4)**.

Summaries: When enough data was available, we summarized the evidence by presenting meta-analysed pooled estimates with 95% CIs by 4-week blocks (see **Appendix 4** for details). For meta-analyses, sub-groups were considered as separate cohorts. Where data was insufficient, we provide an average (and range) of the available VE data or point estimate (and 95%CIs) in there was only a single study.

We update this document every 4th Wednesday and post it on the COVID-END website.

Highlights of changes in this version

- We now provide meta-analysed VE point estimates and CIs for fully vaccine schedule data
- Follow-ups have been extended to 44+ weeks post receipt of a full vaccine schedule
- Three studies provide data on the Omicron variant
- Two studies have been included that report on the long-term VEs of additional doses beyond the full vaccine schedule

Visual representation of data

- **Percentages** indicate *level of effectiveness* from 0% (no effect) to 100% (full protection): meta-analysed point estimates and 95% CIs are provided, along with the number of cohorts contributing to the data.
- **Colour** indicates **Level of Certainty** based on the evidence

High certainty evidence	Moderate certainty evidence	Low certainty evidence
pooling of low to moderate risk of bias RCTs or pooling of observational studies with low risk of bias and consistent findings	single RCT with low to moderate risk of bias or >one observational study with low to moderate risk of bias and at least partially consistent findings	single RCT or observational study with serious risk of bias or multiple low to serious risk of bias observational studies with inconsistent findings

Question 1a: VE against COVID-19 infections change over time (>112 days) in individuals who have received a complete primary COVID-19 vaccine series

Table 1: VE against COVID-19 cases* for completed primary series (**all strains**)

	Baseline days (weeks)		**Follow-up days (weeks)**								
	0-13 (0-2)	**14-42 (2-6)**	**112-139 (12-16)**	**140-167 (16-20)**	**168-195 (20-24)**	**196-223 (24-28)**	**224-251 (28-32)**	**252-279 (32-36)**	**280-307 (36-40)**	**308-335 (40-44)**	**336+ (44+)**
Any vaccine	64% (51-74) 9 cohorts	90% (88-92) 54 cohorts	76% (72-80) 34 cohorts	73% (69-76) 51 cohorts	69% (63-73) 37 cohorts	67% (56-76) 14 cohorts	39% (13-43) 7 cohorts	50% (9-73) 4 cohorts	33% (-180-84) 2 cohorts	-0.3% (-10-9) 1 cohort	17% (3-28) 1 cohort
Any mRNA vaccine	71% (64-76) 7 cohorts	93% (91-94) 41 cohorts	79% (75-83) 29 cohorts	75% (72-78) 40 cohorts	73% (67-77) 29 cohorts	68% (55-77) 13 cohorts	31% (-3-54) 5 cohorts	50% (-11-77) 3 cohorts	33% (-180-84) 2 cohorts	0.3% (-10-9) 1 cohort	17% (3-28) 1 cohort
Any adenovirus	34% (-11-60) 2 cohorts	71% (66-75) 11 cohorts	50% (36-60) 4 cohorts	61% (51-70) 10 cohorts	54% (38-65) 8 cohorts	54% (51-57) 1 cohort	56 % (-111-91) 2 cohorts	50% (42-57) 1 cohort			
BNT162b2	71% (62-78) 5 cohorts	92% (90-93) 17 cohorts	76% (69-82) 12 cohorts	67% (63-71) 18 cohorts	57% (48-65) 16 cohorts	65% (42-79) 7 cohorts	33% (-12-60) 4 cohorts	40% (-61-78) 2 cohorts	-18% (-26-10) 1 cohort	-0.3% (-10-9) 1 cohort	17% (3-28) 1 cohort
mRNA-1273		94% (93-96) 17 cohorts	82% (79-84) 10 cohorts	80% (77-83) 16 cohorts	72% (62-79) 6 cohorts	73% (71-75) 2 cohorts		65% (62-68) 1 cohort	74% (-13-94) 1 cohort		
ChAdOx1	47% (37-56) 1 cohort	76% (72-80) 6 cohorts	25% (-71-67) 2 cohorts	63% (53-71) 5 cohorts	50% (27-65) 2 cohorts						
Ad26.COV2.S	11% (-36-41) 1 cohort	60% (37-74) 3 cohorts	50% (24-67) 3 cohorts	51% (40-61) 3 cohorts	52% (41-61) 4 cohorts	54% (51-57) 1 cohort		50% (42-57) 1 cohort			

* This is a combination of any, symptomatic, and asymptomatic infections. If a study reports any infections this is prioritised over symptomatic or asymptomatic (if reported). If the study reports symptomatic and asymptomatic, then symptomatic is prioritised.

Table 2: VE against COVID-19 cases* for completed primary series (**Delta variant**)

	Baseline days (weeks)		**Follow-up days (weeks)**								
	0-13 (0-2)	**14-42 (2-6)**	**112-139 (12-16)**	**140-167 (16-20)**	**168-195 (20-24)**	**196-223 (24-28)**	**224-251 (28-32)**	**252-279 (32-36)**	**280-307 (36-40)**	**308-335 (40-44)**	**336+ (44+)**
Any vaccine	71% (64-77) 1 cohort	92% (87-95) 13 cohorts	83% (72-90) 9 cohorts	81% (74-86) 14 cohorts	79% (72-84) 6 cohorts	70% (41-85) 5 cohorts	61% (-47-89) 2 cohorts	65% (62-68) 1 cohort	74% (-13-94) 1 cohort		
Any mRNA vaccine	71% (64-77) 1 cohort	93% (91-94) 11 cohorts	83% (72-90) 9 cohorts	82% (75-87) 12 cohorts	77% (70-83) 7 cohorts	71% (41-86) 5 cohorts	24% (18-30) 1 cohort	65% (62-68) 1 cohort	74% (-13-94) 1 cohort		
Any adenovirus		81% (45-94) 2 cohorts		74% (-16-94) 2 cohorts	85% (83-87) 1 cohort		80% (74-85) 1 cohort				
BNT162b2	71% (64-77) 1 cohort	92% (82-96) 5 cohorts	88% (85-90) 2 cohorts	75% (63-83) 4 cohorts	74% (45-88) 3 cohorts	80% (75-84) 2 cohorts					
mRNA-1273		92% (78-97) 5 cohorts	82% (79-85) 4 cohorts	83% (69-90) 7 cohorts	75% (74-76) 2 cohorts	73% (71-75) 1 cohort		65% (62-68) 1 cohort	74% (-13-94) 1 cohort		
ChAdOx1											
Ad26.COV2.S											

* This is a combination of any, symptomatic, and asymptomatic infections. If a study reports any infections this is prioritised over symptomatic or asymptomatic (if reported). If the study reports symptomatic and asymptomatic, then symptomatic is prioritised.

Table 3: VE against COVID-19 cases* for completed primary series (**Omicron variant**)

	Baseline days (weeks)		**Follow-up days (weeks)**								
	0-13 (0-2)	**14-42 (2-6)**	**112-139 (12-16)**	**140-167 (16-20)**	**168-195 (20-24)**	**196-223 (24-28)**	**224-251 (28-32)**	**252-279 (32-36)**	**280-307 (36-40)**	**308-335 (40-44)**	**336+ (44+)**
Any vaccine		50% (17-70) 2 cohorts	29% (18-38) 1 cohort	14% (17-20) 2 cohorts	8% (7-20) 2 cohorts	50% (2-16) 1 cohort	-6% (-13-1) 2 cohorts	2% (-6-9) 1 cohort	-18% (-26 - -10) 1 cohort	-0.3% (-10-9) 1 cohort	17% (3-28) 1 cohort
Any mRNA vaccine		62% (50-72) 1 cohort	29% (18-38) 1 cohort	11% (-3-22) 1 cohort	14% (6-22) 1 cohort	50% (2-16) 1 cohort	-8% (-15- -0.2) 1 cohort	2% (-6-9) 1 cohort	-18% (-26-10) 1 cohort	-0.3% (-10-9) 1 cohort	17% (3-28) 1 cohort
Any adenovirus		36% (24-46) 1 cohort		15% (7-22) 1 cohort	1% (-9-10) 1 cohort		2% (-17-18) 1 cohort				
BNT162b2											
mRNA-1273											
ChAdOx1											
Ad26.COV2.S											

Question 1b: VE against COVID-19 hospitalisations change over time (>112 days) in individuals who have received a complete primary COVID-19 vaccine series

Table 4: VE against COVID-19 hospitalisations for completed primary series (**all strains**)

	Baseline days (weeks)		**Follow-up days (weeks)**								
	0-13 (0-2)	**14-42 (2-6)**	**112-139 (12-16)**	**140-167 (16-20)**	**168-195 (20-24)**	**196-223 (24-28)**	**224-251 (28-32)**	**252-279 (32-36)**	**280-307 (36-40)**	**308-335 (40-44)**	**336+ (44+)**
Any vaccine	100% (100-100) 5 cohorts	94% (93-96) 32 cohorts	92% (94-100) 22 cohorts	92% (94-100) 29 cohorts	93% (95-100) 16 cohorts	95% (91-97) 1 cohort	88% (85-90) 1 cohort				
Any mRNA vaccine	100% (100-100) 3 cohorts	95% (93-96) 24 cohorts	92% (90-94) 18 cohorts	93% (88-94) 21 cohorts	99% (88-100) 13 cohorts	95% (91-97) 1 cohort	88% (85-90) 1 cohort				
Any adenovirus	100% (100-100) 2 cohorts	90% (76-96) 5 cohorts	81% (73-87) 1 cohort	87% (81-91) 5 cohorts	100% (75-100) 3 cohorts						
BNT162b2		95% (92-97) 9 cohorts	95% (91-97) 6 cohorts	93% (91-95) 8 cohorts	99.5% (42-100) 4 cohorts		88% (85-90) 1 cohort				
mRNA-1273	100% (100-100) 1 cohort	96% (96-97) 7 cohorts	89% (84-93) 5 cohorts	95% (94-96) 6 cohorts	99.9% (-49-100) 2 cohorts	95% (91-97) 1 cohort					
ChAdOx1	100% (100-100) 2 cohorts	92% (79-97) 4 cohorts		88% (80-93) 4 cohorts	100% (100-100) 2 cohorts						
Ad26.COV2.S		77% (68-85) 1 cohort	81% (73-87) 1 cohort	83% (76-87) 1 cohort	82% (67-89) 1 cohort						

Table 5: VE against COVID-19 hospitalisations for completed primary series (**Delta variant**)

	Baseline days (weeks)		**Follow-up days (weeks)**								
	0-13 (0-2)	**14-42 (2-6)**	**112-139 (12-16)**	**140-167 (16-20)**	**168-195 (20-24)**	**196-223 (24-28)**	**224-251 (28-32)**	**252-279 (32-36)**	**280-307 (36-40)**	**308-335 (40-44)**	**336+ (44+)**
Any vaccine	100% (100-100) 2 cohorts	97% (95-98) 10 cohorts	92% (90-94) 10 cohorts	91% (86-94) 9 cohorts	99% (37-100) 5 cohorts						
Any mRNA vaccine	100 % (100-100) 1 cohort	97% (93-99) 6 cohorts	93% (89-96) 7 cohorts	91% (83-95) 5 cohorts	96% (82-99) 4 cohorts						
Any adenovirus	100 % (100-100) 1 cohort	95% (95-96) 1 cohort	80% (77-83) 1 cohort	100% (100-100) 1 cohort							
BNT162b2		97% (88-99) 2 cohorts	97% (88-99) 2 cohorts	92% (90-93) 2 cohorts	98% (91-99.6) 1 cohort						
mRNA-1273		98% (89-96) 1 cohort		87% (72-94) 1 cohort							
ChAdOx1	100 % (100-100) 1 cohort	95% (95-96) 1 cohort		80% (77-83) 1 cohort	100% (100-100) 1 cohort						
Ad26.COV2.S											

Table 6: VE against COVID-19 hospitalisations for completed primary series (**Omicron variant**)

	Baseline days (weeks)		**Follow-up days (weeks)**								
	0-13 (0-2)	**14-42 (2-6)**	**112-139 (12-16)**	**140-167 (16-20)**	**168-195 (20-24)**	**196-223 (24-28)**	**224-251 (28-32)**	**252-279 (32-36)**	**280-307 (36-40)**	**308-335 (40-44)**	**336+ (44+)**
Any vaccine		71% (51-83) 1 cohort	58% (38-71) 1 cohort	54% (48-59) 1 cohort							
Any mRNA vaccine		71% (51-83) 1 cohort	58% (38-71) 1 cohort	54% (48-59) 1 cohort							
Any adenovirus											
BNT162b2											
mRNA-1273											
ChAdOx1											
Ad26.COV2.S											

Question 1c: VE against COVID-19 deaths change over time (>112 days) in individuals who have received a complete primary COVID-19 vaccine series

Table 7: VE against COVID-19 deaths for completed primary series (**all strains**)

	Baseline days (weeks)		**Follow-up days (weeks)**								
	0-13 (0-2)	**14-42 (2-6)**	**112-139 (12-16)**	**140-167 (16-20)**	**168-195 (20-24)**	**196-223 (24-28)**	**224-251 (28-32)**	**252-279 (32-36)**	**280-307 (36-40)**	**308-335 (40-44)**	**336+ (44+)**
Any vaccine		93% (90-96) 13 cohorts	76% (38-91) 1 cohort	85% (67-93) 3 cohorts	88% (84-90) 11 cohorts						
Any mRNA vaccine		96% (98-93) 7 cohorts		92% (89-95) 1 cohort	90 % (85-93) 6 cohorts						
Any adenovirus		88% (66-96) 5 cohorts	76% (38-91) 1 cohort	78% (53-87) 2 cohorts	84% (74-90) 4 cohorts						
BNT162b2		96% (93-98) 4 cohorts		92% (89-95) 1 cohort	90% (84-93) 3 cohorts						
mRNA-1273		98% (86-99) 2 cohorts			95% (90-98) 2 cohorts						
ChAdOx1		95% (96-93) 2 cohorts		85% (77-90) 1 cohort	88% (81-93) 2 cohorts						
Ad26.COV2.S		63% (48-74) 2 cohorts	76% (38-91) 1 cohort	68% (42-82) 1 cohort	77% (60-86) 2 cohorts						

Table 8: VE against COVID-19 deaths for completed primary series (**Delta variant**)

	Baseline days (weeks)		Follow-up days (weeks)								
	0-13 (0-2)	**14-42 (2-6)**	**112-139 (12-16)**	**140-167 (16-20)**	**168-195 (20-24)**	**196-223 (24-28)**	**224-251 (28-32)**	**252-279 (32-36)**	**280-307 (36-40)**	**308-335 (40-44)**	**336+ (44+)**
Any vaccine		97% (90-91) 2 cohorts		89% (80-94) 2 cohorts							
Any mRNA vaccine											
Any adenovirus											
BNT162b2		99% (97-99.4) 1 cohort		94% (89-94) 1 cohort							
mRNA-1273											
ChAdOx1		95% (93-96) 1 cohort		84% (76-90) 1 cohort							
Ad26.COV2.S											

Table 9: VE against COVID-19 deaths for completed primary series (**Omicron variant**)

No data to report

Question 2a: VE against COVID-19 infections change over time (>84 days) in individuals who have received a complete primary COVID-19 vaccine series plus an additional dose

Table 10: VE against COVID-19 infections for completed primary series and an additional dose

	Baseline days (weeks)		**Follow-up days (weeks)**								
	0-13 (0-2)	**14-42 (2-6)**	**84-111 (8-12)**	**112-139 (12-16)**	**140-167 (16-20)**	**168-195 (20-24)**	**196-223 (24-28)**	**224-251 (28-32)**	**252-279 (32-36)**	**280-307 (36-40)**	**308-335 (40-44)**
Any vaccine											
Any mRNA vaccine											
Any adenovirus											
BNT162b2 - **Omicron**	16 % (1-28) 1 cohort	54 % (47-59) 1 cohort	38 % (29-45) 1 cohort								
mRNA-1273											
ChAdOx1											
Ad26.COV2.S											

Question 2b: VE against COVID-19 hospitalisations change over time (>84 days) in individuals who have received a complete primary COVID-19 vaccine series plus an additional dose

Table 11: VE against COVID-19 hospitalisations for completed primary series and an additional dose

	Baseline days (weeks)		**Follow-up days (weeks)**								
	0-13 (0-2)	**14-42 (2-6)**	**84-111 (8-12)**	**112-139 (12-16)**	**140-167 (16-20)**	**168-195 (20-24)**	**196-223 (24-28)**	**224-251 (28-32)**	**252-279 (32-36)**	**280-307 (36-40)**	**308-335 (40-44)**
Any vaccine											
Any mRNA vaccine – **all strains**		95 % (94-95) 1 cohort	81 % (72-87) 1 cohort								
Any mRNA vaccine – **Delta**		96 % (95-97) 1 cohort	76 % (14-93) 1 cohort								
Any mRNA vaccine – **Omicron**		91 % (88-93) 1 cohort	78 % (67-85) 1 cohort								
Any adenovirus											
BNT162b2											
mRNA-1273											
ChAdOx1											
Ad26.COV2.S											

Question 2c: VE against COVID-19 deaths change over time (>84 days) in individuals who have received a complete primary COVID-19 vaccine series plus an additional dose

Table 12: VE against COVID-19 deaths for completed primary series and an additional dose

No data to report

Narrative overview of findings

1a. Findings for confirmed COVID-19 cases primary series only

A total of 23 studies (covering 63 cohorts) provided usable baseline and follow-up information with regards to COVID-19 related cases. The meta-analyses indicated that there was a consistent decline in the VE of the vaccines for cases, especially up to 32 weeks post full vaccine schedule. The decline was similar across all vaccines, with the overall VE being greater for any mRNA vs. adenovirus and for mRNA-1273 being greater than BNT162b2. With regards to variants, compared to the combined data the patterns of responses was similar for the Delta variant. There were only two studies that provided data for Omicron, which showed a lower baseline VE compared to Delta and an inconsistent pattern over the follow-up period.

1b. Findings for COVID-19 related hospitalisations primary series only

A total of 11 studies (covering 37 cohorts) provided usable baseline and follow-up information with regards to COVID-19 related hospitalisations. The meta-analyses indicated that there was a great deal of consistency across time in the ability of the vaccines to prevent COVID-19-related hospitalisations, especially across the 24 weeks post receipt of a vaccine series (and possibly out to 32 weeks). The results were consistent across vaccines, though mRNA vaccines tended to provide greater protection than adenovirus-based vaccines. With regards to variants, compared to the combined data the patterns of responses was similar for the Delta variant. There was only study that provided data for Omicron, which showed a lower baseline VE compared to Delta and a graded decrease in VE across the 20 weeks post vaccine series.

1c. Findings for COVID-19 related deaths primary series only

A total of 4 studies (covering 13 cohorts) provided usable baseline and follow-up information with regards to COVID-19 related deaths. The meta-analyses indicated that there was a great deal of consistency across time in the ability of the vaccines to prevent COVID-19-related deaths, especially across the 24 weeks post receipt of a vaccine series. The results were consistent across vaccines, with minimal differences between mRNA and adenovirus vaccines. Finally, with regards to variants, there was minimal data for the Delta variant (suggestion that VE remained high up to 24 weeks post vaccine series) and no data for the Omicron variant.

2a. Findings for confirmed COVID-19 cases primary series plus additional dose

A total of one study provided usable baseline and follow-up information with regards to confirmed COVID-19 case data (symptomatic cases). The study included members from the general population of Qatar (December 2021 to February 2022) and reported on data for the VE of the BNT162b2 vaccine against Omicron (inferred from Omicron wave – 95% of cases at that time were Omicron). After a small improvement in VE (54%) there was a reduction at 84 days (38%). Of note, this is the same cohort who provided generally lower VEs for cases in response to a full vaccine series.

2b. Findings for COVID-19 related hospitalisations primary series plus additional dose

A total of one study provided usable baseline and follow-up information with regards to COVID-19-related hospitalisations. The study included individuals from 10 states in the USA (August 2021 to January 2022) and reported on data for the VE of any mRNA vaccine against any strain, and the Delta and Omicron variants (inferred from variant predominant periods based on state-level surveillance data). In general, 3-dose VE for hospitalisations had a small amount of waning approximately 12+ weeks after administration (from 91-96% to 76-81%) with a 20% drop against Delta and a 13% drop against Omicron. Of note, this study also assessed VE against a full vaccine schedule during the same period and found that 2-dose VE dropped 4% against Delta and 13% against Omicron.

2c. Findings for COVID-19 related deaths primary series plus additional dose
There were no studies that provided usable baseline and follow-up information with regards to COVID-19-related hospitalisations.

Risk of bias assessment
The risk of bias data for each individual study is provided in the Supplementary File (10.3_vaccine_waning_adults_RoB_2022-03-02.xlsx). Overall, the risk of bias was serious for the majority of studies due to the lack of adjustment of prognostic factors. Beyond that most items were related low. One study (Young-Xu et al.) was deemed as having a critical RoB due to not accounting for calendar time. Exclusion of this data had minimal impacts on the nature of the reported results.

Strengths and Limitations
Key strengths of the present review include the broad search terms that were included during the initial screening phase, the rigorous methodologies that were employed throughout the review, and validation processes that were included to ensure consistency. In spite of these strengths, there were several limitations that need to be noted. As with any rapid review process, there is a slightly increased possibility that studies might be missed when compared to a full systematic review. However, this was potentially mitigated as we validated our study inclusions against another evidence synthesis team. Due to the turnaround time for the review, we were also limited in the scope of potential sub-groups that could be included and we were not able to extract any immunogenicity data. However, we were able to identify data for several key sub-groups within the extracted studies. The lack of time also meant that we weren't able to contact authors for studies that could have potentially provided data, which means that some studies which had the potential to be included, were excluded (e.g., those that graphed data but did not provide explicit data within the manuscript).

Potential implications for health systems decision-making
Though the current review provides some initial evidence for a waning in VE for COVID-19 confirmed cases, it is unclear what might be driving this (e.g., a degradation in immunogenicity, changes in public health measures, or variations in case numbers and general transmission). Contrasting this are relatively stable VEs for COVID-related hospitalisations and deaths. These patterns seem to be consistent for the Delta variant. However, there is current limited published data on the longer-term impacts of vaccines on Omicron related outcomes.

With regards to long-term waning of an additional vaccine dose. There is currently limited data to provide any notable guidance. The minimal data obtained from two studies indicates that potential waning in VEs for both cases and hospitalisations by 8 weeks post booster dose, with equivalent results for the Delta and Omicron variants.

Given that Omicron has become the dominant variant in Canada, to reduce the transmission of the virus and limit increases in cases, there may be a need to maintain some COVID-19 prevention behaviours, e.g., mask wearing and physical distancing, in individuals who are fully vaccinated with or without an additional dose. Once again, this needs to be considered in the context of the limited number of studies available looking at multiple transmission prevention strategies and a lack of randomised controlled trial evidence on the utility of combinations of prevention measures.

Land Acknowledgements
The Montreal Behavioural Medicine Centre, Concordia University, UQAM, and the CIUSSS-NIM are located on unceded Indigenous lands. The Kanien'kehá:ka Nation is recognized as the custodians of the lands and waters on which these institutions stand today. Tiohtiá:ke commonly known as Montreal is historically known as a gathering place for many First Nations. Today, it is home to a diverse population of Indigenous and other

peoples. We respect the continued connections with the past, present, and future in our ongoing relationships with Indigenous and other peoples within the Montreal community.

SPOR Evidence Alliance operates from the St. Michael's Hospital, Unity Health Toronto which is located on the traditional land of the Huron-Wendat, the Seneca, and the Mississaugas of the Credit. Today, this meeting place is still the home to many Indigenous people from across Turtle Island.

COVID-END is housed within McMaster University which is located on the traditional territories of the Mississauga and Haudenosaunee nations, and within the lands protected by the "Dish With One Spoon" wampum, an agreement to peaceably share and care for the resources around the Great Lakes.

We are grateful to have the opportunity to work on these lands.

Funding
To help Canadian decision-makers as they respond to unprecedented challenges related to the COVID-19 pandemic, COVID-END in Canada is preparing rapid evidence responses like this one. The development and continued updating of this living evidence synthesis has been funded by the Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada. The opinions, results, and conclusions are those of the team that prepared the living evidence synthesis, and independent of the Government of Canada, CIHR and the Public Health Agency of Canada. No endorsement by the Government of Canada, CIHR or Public Health Agency of Canada is intended or should be inferred.

The members of the Montreal Behavioural Medicine Centre are supported by a variety of career and scholarship awards. Dr. Bacon is supported by the CIHR-SPOR initiative through the Mentoring Chair program (SMC-151518) and by the Fonds de recherche du Québec: Santé (FRQS) through the Chaire de recherche double en Intelligence Artificielle / Santé Numérique ET sciences de la vie program (309811). Drs. Wu and Joyal-Desmarias are supported by the CIHR-SPOR Mentoring Chair program (SMC-151518). Ms. Vieira is supported by a FRQS PhD scholarship.

Citation
Bacon SL, Ribeiro PAB, Yip D, Wu N, Vieira AM, Joyal-Desmarais K, Stojanovic J. COVID-19 living evidence synthesis #10 (version 10.3): What is the long-term effectiveness of available COVID-19 vaccines for adults, including for variants of concern and over time frames beyond 112 days in those with a primary series and beyond 84 days in those with a primary series and an additional dose? The Montreal Behavioural Medicine Centre, META group, 2nd March 2022.